Get Well Appoints Thomas Elbert as Chief Operating Officer

1 year ago

Executive brings more than 20 years of healthcare information technology, data architecture, and analytics experience BETHESDA, Md., Nov. 1, 2024…

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

1 year ago

WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing…

UnisLink Earns HITRUST I1 Certification to Manage Data Protection and Mitigate Cybersecurity Threats

1 year ago

HITRUST certification validates that UnisLink is operating with leading security practices to protect sensitive information.PHOENIX, AZ / ACCESSWIRE / November…

Nation’s Largest Pancreatic Cancer Early Detection Study Holds Annual Meeting in San Diego

1 year ago

PRECEDE Study Aims to Increase Early Detection in Pancreatic CancerSAN DIEGO, CA / ACCESSWIRE / November 1, 2024 / Pancreatic…

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

1 year ago

HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company…

RTI Surgical Completes Acquisition of Collagen Solutions

1 year ago

RTI Surgical Completes Acquisition of Collagen Solutions ALACHUA, Fla., November 1, 2024 – RTI Surgical ("RTI" or "the Company"), a…

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

1 year ago

FemBloc issued patent provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth controlATLANTA, Nov. 01, 2024 (GLOBE…

Galecto Reports Third Quarter 2024 Financial Results

1 year ago

-  Completed strategic review to focus on oncology and severe liver diseases -  Announced acquisition of global rights to BRM-1420,…

Record Monthly Enrollment Achieved in SeaStar Medical’s Pivotal Adult AKI Trial

1 year ago

DENVER, Nov. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary…

Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial

1 year ago

Bagsværd, Denmark, 1 November 2024 – Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE…